Trinity Biotech is an Irish diagnostics issuer whose residual equity now sits under a senior secured claim that is larger than the entire operating franchise. The investment debate is whether an outsourced manufacturing overhaul in rapid HIV testing can turn a disrupted global-health product line into enough cash to service that claim before listing and liquidity events force another recapitalization. The first-quarter rebound in TrinScreen HIV and haemoglobin sales is the first clean operating evidence that demand is returning after last year's aid-funding shock. It is not yet evidence that the residual claim is safe.
HIV sales recovered sharply in the opening quarter as TrinScreen volumes rebuilt from a depressed year-ago base, and haemoglobin products also contributed. Gross margin expanded as lower-cost outsourced production began to show through, and the adjusted operating loss narrowed. Those are real operating gains. They still sit on a balance sheet that classifies the Perceptive term loan as a current liability, holds only a thin cash balance, and reports a large accumulated deficit. Preliminary second-quarter revenue was described as broadly consistent with the first quarter, which implies the rebound is holding but not accelerating.
The next several months resolve three named questions. First, whether UniGold HIV outsourced scale-up in the third quarter converts the order book into cash rather than working-capital noise. Second, whether the Nasdaq hearing on the market-value-of-publicly-held-shares shortfall produces an extension rather than a delisting path. Third, whether the CGM+ wearable program and the Trinovium cooling subsidiary remain funded options or become cash drains that the lender is no longer willing to underwrite. The market capitalization prices the equity as a thin option on that sequence.